Elizabeth Gardner


Older Breast Cancer Patients Require Special Consideration

September 17th 2017

Treating older patients with breast cancer must include more quality of life considerations and different types of survival calculations.

Stage, ER Status Guide HER2 Therapy Selection in Breast Cancer

September 17th 2017

The sequencing of therapies for patients with HER2-positive breast cancer is largely driven by stage of disease and hormone receptor status.

Ovarian Suppression Individualization Warranted in Breast Cancer

September 16th 2017

Patients have a hard time with artificially induced menopause and some research suggests it may have a negligible effect on the success of their treatment.

Multigene Testing Adds Complexity to Decision Making Process

September 16th 2017

Multigene panel testing offers a new but often puzzling tool for breast cancer treatment, since the results are often difficult to interpret, both for relative risk and risk management.

IBM's Watson has Potential Partnership With Oncologists

September 16th 2017

Even with advancements in technology, the prospect of artificial intelligence treating patients with cancer still remains out of reach. At least, for now.

"Opioid Epidemic" Increases Challenge of Treating Cancer Pain

September 15th 2017

Extra vigilance, careful management, and an emphasis on empathy makes treating cancer pain more effective during an opioid addiction epidemic.

Physicians on the Offense: Get Organized to Thrive in This Payment Arena

November 7th 2015

The keynote address at the 2015 LUGPA Annual Meeting urged physicians to band together and create an offensive strategy when it comes to the nation's healthcare system.

Deliver Androgen Blockade at Prostate Cancer Cells to Achieve Castrate Levels

November 6th 2015

Hormone therapies for prostate cancer aimed at reducing serum androgens are trained on the wrong target: the testes and the adrenal glands. Rather, they should attack the prostate cancer cells themselves.

Crawford Questions ADT Standards, Approaches in Prostate Cancer

November 6th 2015

E. David Crawford, MD, discussed issues with FDA standards for ADT agents and current treatment approaches to androgen deprivation in prostate cancer at the 2015 LUGPA Annual Meeting.